MX391620B - Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). - Google Patents

Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).

Info

Publication number
MX391620B
MX391620B MX2019012375A MX2019012375A MX391620B MX 391620 B MX391620 B MX 391620B MX 2019012375 A MX2019012375 A MX 2019012375A MX 2019012375 A MX2019012375 A MX 2019012375A MX 391620 B MX391620 B MX 391620B
Authority
MX
Mexico
Prior art keywords
lfa
associated antigen
lymphocyte function
inhibitor formulations
compound
Prior art date
Application number
MX2019012375A
Other languages
English (en)
Spanish (es)
Other versions
MX2019012375A (es
Inventor
Mary Newman
William Hunke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX391620(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019012375A publication Critical patent/MX2019012375A/es
Publication of MX391620B publication Critical patent/MX391620B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2019012375A 2012-12-19 2013-12-18 Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). MX391620B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739609P 2012-12-19 2012-12-19
US201361758147P 2013-01-29 2013-01-29
PCT/US2013/076041 WO2014100135A1 (en) 2012-12-19 2013-12-18 Lfa-1 inhibitor formulations

Publications (2)

Publication Number Publication Date
MX2019012375A MX2019012375A (es) 2020-01-20
MX391620B true MX391620B (es) 2025-03-19

Family

ID=50979140

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012375A MX391620B (es) 2012-12-19 2013-12-18 Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
MX2015007540A MX368876B (es) 2012-12-19 2013-12-18 Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015007540A MX368876B (es) 2012-12-19 2013-12-18 Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).

Country Status (20)

Country Link
US (2) US11058677B2 (enExample)
EP (2) EP3827823A1 (enExample)
JP (1) JP6373867B2 (enExample)
KR (1) KR101891144B1 (enExample)
CN (1) CN104955453B (enExample)
AU (1) AU2013361579B2 (enExample)
BR (1) BR112015014367B1 (enExample)
CA (1) CA2894170C (enExample)
DK (1) DK2934510T3 (enExample)
EA (2) EA201791321A1 (enExample)
ES (1) ES2846724T3 (enExample)
HU (1) HUE052299T2 (enExample)
IL (1) IL239490B (enExample)
MX (2) MX391620B (enExample)
NZ (1) NZ708821A (enExample)
PL (1) PL2934510T3 (enExample)
PT (1) PT2934510T (enExample)
SI (1) SI2934510T1 (enExample)
WO (1) WO2014100135A1 (enExample)
ZA (2) ZA201504404B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995439B (zh) * 2016-01-26 2019-09-20 镇江圣安医药有限公司 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019171260A1 (en) * 2018-03-09 2019-09-12 Mankind Pharma Ltd. Pharmaceutical composition of lifitegrast
JP7700045B2 (ja) * 2019-04-18 2025-06-30 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法
EP3842032A1 (en) 2019-12-24 2021-06-30 Warszawskie Zaklady Farmaceutyczne Polfa S.A. A pharmaceutical formulation
CN116635032A (zh) * 2020-10-21 2023-08-22 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
CN116211796A (zh) * 2022-12-30 2023-06-06 新领先(重庆)医药科技有限公司 一种立他司特滴眼液及其制备方法
KR20240109779A (ko) * 2023-01-05 2024-07-12 주식회사 종근당 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
KR20250033790A (ko) 2023-09-01 2025-03-10 주식회사 와이에스생명과학 리피테그라스트 함유 점안 조성물
WO2025093739A1 (en) 2023-11-02 2025-05-08 Novaliq Gmbh Semifluorinated alkane compositions comprising lifitegrast
US20250161294A1 (en) * 2023-11-17 2025-05-22 Bausch + Lomb Ireland Limited Compositions and methods for treatment of ocular disorders
CN117771174B (zh) * 2023-12-29 2025-07-29 鲁南贝特制药有限公司 一种立他司特滴眼液及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5429819A (en) * 1992-10-14 1995-07-04 Matsushita Electric Industrial Co., Ltd. Antiviral composition
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
RU2149611C1 (ru) * 1998-04-06 2000-05-27 Московская медицинская академия им. И.М. Сеченова Капли для лечения воспалительных заболеваний глаз (варианты)
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US8877168B1 (en) * 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
FI119361B (fi) 2003-09-26 2008-10-31 Raute Oyj Menetelmä viilun sorvaamiseksi
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
AU2006247136C1 (en) * 2005-05-17 2020-01-16 Bausch + Lomb Ireland Limited Compositions and methods for treatment of eye disorders
EP1901708B1 (en) * 2005-07-08 2013-09-11 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
US7544893B2 (en) 2007-07-25 2009-06-09 Thomas & Betts International, Inc. Extruded wire duct end cap
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
JP2011521896A (ja) 2008-04-15 2011-07-28 サーコード コーポレイション 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
WO2010033800A2 (en) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
WO2010070664A1 (en) * 2008-11-17 2010-06-24 Laila Pharmaceuticals Pvt. Ltd. Curcuminoids and its metabolites for the application in ocular diseases
EP2823814A1 (en) * 2009-06-10 2015-01-14 Mitotech SA Pharmaceutical composition for use in medical and veterinary ophthalmology
KR20110001103A (ko) 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
PH12012501098A1 (en) * 2009-11-23 2014-10-14 Allergan Inc 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
BR112013021048A2 (pt) * 2011-02-18 2016-10-18 M S Appasmy Associates composição oftálmica para permitir dilatação de pupilas
CN103764150A (zh) * 2011-06-29 2014-04-30 阿勒根公司 阿卡他定在治疗荨麻疹中的用途
EP2830627B1 (en) * 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
CN103230583A (zh) * 2013-05-17 2013-08-07 江西省创欣药业集团有限公司 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法

Also Published As

Publication number Publication date
AU2013361579B2 (en) 2018-05-24
IL239490B (en) 2018-12-31
BR112015014367A2 (pt) 2017-07-11
JP2016503058A (ja) 2016-02-01
NZ708821A (en) 2020-03-27
MX2019012375A (es) 2020-01-20
EA201591180A1 (ru) 2015-12-30
CA2894170C (en) 2021-08-10
KR101891144B1 (ko) 2018-08-23
KR20150100763A (ko) 2015-09-02
ZA201504404B (en) 2020-01-29
PT2934510T (pt) 2021-01-13
ZA201608069B (en) 2017-11-29
US20150320737A1 (en) 2015-11-12
DK2934510T3 (da) 2021-01-25
HK1214536A1 (zh) 2016-07-29
HUE052299T2 (hu) 2021-04-28
SI2934510T1 (sl) 2021-02-26
MX368876B (es) 2019-10-21
CA2894170A1 (en) 2014-06-26
JP6373867B2 (ja) 2018-08-15
CN104955453B (zh) 2018-09-18
IL239490A0 (en) 2015-08-31
EP2934510A1 (en) 2015-10-28
US20220000859A1 (en) 2022-01-06
MX2015007540A (es) 2016-04-13
ES2846724T3 (es) 2021-07-29
CN104955453A (zh) 2015-09-30
EA201791321A1 (ru) 2018-04-30
EP3827823A1 (en) 2021-06-02
EP2934510A4 (en) 2016-08-17
HK1214963A1 (en) 2016-08-12
AU2013361579A1 (en) 2015-06-18
EP2934510B1 (en) 2020-10-28
US11058677B2 (en) 2021-07-13
PL2934510T3 (pl) 2021-07-05
EA028008B1 (ru) 2017-09-29
BR112015014367B1 (pt) 2022-11-22
WO2014100135A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
MX391620B (es) Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
CY1124311T1 (el) Παρεμποδιστες dna-pk
BR112015014753A2 (pt) composições, utilização de uma composição, método para o combate dos fungos fitopatogênicos e semente
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
UY35238A (es) Composiciones que comprenden un compuesto de triazol
ECSP13013050A (es) Formulación para anticuerpo anti- 4 7
MX2013004491A (es) Boronatos como inhibidores de arginasa.
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
PH12015501385A1 (en) Autotaxin inhibitors
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
EA201501033A1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3